PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.03
D/E of 0.03 while TRAW has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.
2.11
Net debt 50-75% of TRAW's 2.77. Mohnish Pabrai would check if this competitive advantage in leverage translates to better reinvestment opportunities.
-36.71
Negative coverage while TRAW shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
2.36
Current ratio 1.25-1.5x TRAW's 2.11. Mohnish Pabrai would examine if this strength creates buying power advantages.
No Data
No Data available this quarter, please select a different quarter.